Integrity Applications Appoints Chairman & CEO

The Board of Directors of Integrity Applications Inc., maker of GlucoTrack, a noninvasive device for measuring glucose levels of people with Type 2 diabetes and pre-diabetics, announced that it has appointed veteran pharmaceutical executive John Graham CEO, chairman, and director of the company, succeeding Avner Gal, co-founder, effective March 20, 2017. The board also appointed veteran medtech executive Angela Strand as vice chairman, and announced the resignation of Phil Darivoff from the board. Additionally, the company announced that David Malka, co-founder and Vice-President will expand his scope of operational responsibility and that Eran Cohen, the company’s COO, will be leaving the company.
 
“John is clearly the leader for Integrity’s future, and he has the unanimous support of the Board of Directors. We’ve selected a very strong leader at a time when Integrity is transitioning from a development to a commercial stage company,” said Angela Strand, vice chairman and chairman of the Nominating and Governance Committee. “John’s extensive track record of building successful companies and deep understanding of the diabetes market will enable us to realize our goal of making GlucoTrack the worldwide standard of care for people with diabetes.”
 
John’s three decades of global executive and leadership experience includes 18 years with Aventis and predecessor companies, where he held responsibilities in Germany, Latin America, and the United States. While at Aventis, John orchestrated the market strategy and development for the company’s diabetes franchise, which included the global launch of blockbuster oral antidiabetic Amaryl. He was also instrumental in the development and launch of Lantus, a blockbuster long-acting insulin analogue that has transformed diabetes therapy and is one of the world’s leading insulin brands. John was most recently CEO of the Invida Group, a pan-Asian specialty pharma company based in Singapore, which he transformed and sold to the Menarini Group in 2011. Upon leaving Menarini in 2015, he joined Torreya Partners, a New York based M&A advisory firm, as a Senior Advisor.
 
“Avner and his team have achieved a remarkable accomplishment with the development of GlucoTrack. I joined Integrity because I wanted to be part of a company with disruptive potential. I look forward to working with the employees and the board to build a global enterprise that fully realizes the value of this important device for diabetic patients, clinicians and shareholders,” said John Graham, CEO of Integrity.
 
“The board is grateful for Avner’s leadership and dedication to the company as CEO and Chairman. He deserves incredible recognition for what he has accomplished. We are also thankful for Phil’s service to the board during this transition period, and his continued support of the company as one of its largest individual shareholders,” said Angela Strand, vice chairman. “The board has been focused on expanding the leadership of the company, which we believe is now very well positioned to drive success in this next phase.”